Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.11, $0.13 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $244.32 million versus the consensus estimate of $239.55 million.

GUIDANCE:

Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.06 billion.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)
• Xi urges U.S., Iran to return to track of resolving issues through negotiation as soon as possible - Xinhua
• Alaska Air expects Boeing 737 MAX 10 certification this month